

Rafael Bañares

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2592228/publications.pdf>

Version: 2024-02-01

86
papers

5,550
citations

126907

33
h-index

82547

72
g-index

91
all docs

91
docs citations

91
times ranked

5054
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatitis C eradication improves cognitive function in patients with or without cirrhosis: A prospective real-life study. <i>European Journal of Neurology</i> , 2022, 29, 400-412.	3.3	12
2	Decreased Long-Term Severe Acute Respiratory Syndrome Coronavirus 2-Specific Humoral Immunity in Liver Transplantation Recipients 12 Months After Coronavirus Disease 2019. <i>Liver Transplantation</i> , 2022, 28, 1039-1050.	2.4	9
3	Fully covered metal stent placement as first-line endoscopic treatment for complicated portal cavernoma cholangiopathy. <i>Liver International</i> , 2022, 42, 710-713.	3.9	1
4	HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. <i>Journal of Hepatology</i> , 2022, 76, 812-821.	3.7	59
5	Sinusoidal obstruction syndrome after liver transplantation: A multicenter observational study. <i>Liver Transplantation</i> , 2022, 28, 1257-1261.	2.4	2
6	Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH). <i>Gastroenterología Y Hepatología</i> , 2022, 45, 724-734.	0.5	3
7	A Shortcut from Metabolic-Associated Fatty Liver Disease (MAFLD) to Hepatocellular Carcinoma (HCC): c-MYC a Promising Target for Preventative Strategies and Individualized Therapy. <i>Cancers</i> , 2022, 14, 192.	3.7	15
8	ESOPHAGOGASTRIC VARICEAL BLEEDING AS DEBUT OF CAROLI'S SYNDROME: A REPORTED CASE. <i>Revista Española De Enfermedades Digestivas</i> , 2022, , .	0.3	0
9	International multicenter validation of <scp>GES</scp> score for <scp>HCC</scp> risk stratification in chronic hepatitis C patients. <i>Journal of Viral Hepatitis</i> , 2022, 29, 807-816.	2.0	4
10	Massive impact of coronavirus disease 2019 pandemic on gastroenterology and hepatology departments and doctors in Spain. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1627-1633.	2.8	19
11	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 1097-1108.	3.7	149
12	Reply to: "Open or closed window: That is the question". <i>Journal of Hepatology</i> , 2021, 74, 486-487.	3.7	0
13	Molecular Profiling of Decompensated Cirrhosis by a Novel MicroRNA Signature. <i>Hepatology Communications</i> , 2021, 5, 309-322.	4.3	13
14	Possible unrecognised liver injury is associated with mortality in critically ill COVID-19 patients. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110234.	3.2	7
15	Liver X Receptor Exerts Anti-Inflammatory Effects in Colonic Epithelial Cells via <i>ABCA1</i> and Its Expression Is Decreased in Human and Experimental Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1661-1673.	1.9	5
16	A simple nomogram identifies patients with refractory ascites with worse outcome after transjugular intrahepatic portosystemic shunt. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, e587-e593.	1.6	1
17	Acute-on-chronic liver failure: A distinct clinical syndrome. <i>Journal of Hepatology</i> , 2021, 75, S27-S35.	3.7	55
18	Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis. <i>Journal of Hepatology</i> , 2021, 75, 342-350.	3.7	28

#	ARTICLE	IF	CITATIONS
19	Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 75, 589-599.	3.7	36
20	Fat: Quality, or Quantity? What Matters Most for the Progression of Metabolic Associated Fatty Liver Disease (MAFLD). <i>Biomedicines</i> , 2021, 9, 1289.	3.2	4
21	Hepatocellular carcinoma risk after viral response in hepatitis C virus-advanced fibrosis: Who to screen and for how long?. <i>World Journal of Gastroenterology</i> , 2021, 27, 6737-6749.	3.3	11
22	Lowering Portal Pressure Improves Outcomes of Patients With Cirrhosis, With or Without Ascites: A Meta-Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 313-327.e6.	4.4	74
23	Prevalence, features and predictive factors of liver nodules in Fontan surgery patients: The VALDIG Fonliver prospective cohort. <i>Journal of Hepatology</i> , 2020, 72, 702-710.	3.7	45
24	Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF. <i>Journal of Hepatology</i> , 2020, 72, 688-701.	3.7	223
25	A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus-Advanced Fibrosis. <i>Hepatology</i> , 2020, 72, 1924-1934.	7.3	56
26	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. <i>Journal of Hepatology</i> , 2020, 73, 842-854.	3.7	282
27	Reply to: "Pre-emptive TIPS for acute variceal bleeding in acute-on-chronic liver failure: Is there enough evidence for a routine recommendation?" <i>Journal of Hepatology</i> , 2020, 73, 977-979.	3.7	0
28	Reply to: "Beta-blockers in refractory ascites" is it truly the end of the road? <i>Journal of Hepatology</i> , 2020, 73, 1291-1292.	3.7	1
29	Elevation of Liver Fibrosis Index FIB-4 Is Associated With Poor Clinical Outcomes in Patients With COVID-19. <i>Journal of Infectious Diseases</i> , 2020, 222, 726-733.	4.0	43
30	Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension. <i>Journal of Hepatology</i> , 2020, 73, 1415-1424.	3.7	104
31	Intraoperative Troponin Elevation in Liver Transplantation Is Independently Associated With Mortality: A Prospective Observational Study. <i>Liver Transplantation</i> , 2020, 26, 681-692.	2.4	3
32	Genetic variants of innate immunity receptors are associated with mortality in cirrhotic patients with bacterial infection. <i>Liver International</i> , 2020, 40, 646-653.	3.9	10
33	Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS. <i>Journal of Hepatology</i> , 2020, 73, 1082-1091.	3.7	112
34	Non-selective beta-blockers impair global circulatory homeostasis and renal function in cirrhotic patients with refractory ascites. <i>Journal of Hepatology</i> , 2020, 73, 1404-1414.	3.7	58
35	Intestinal Epithelial Cell-Derived Extracellular Vesicles Modulate Hepatic Injury via the Gut-Liver Axis During Acute Alcohol Injury. <i>Frontiers in Pharmacology</i> , 2020, 11, 603771.	3.5	17
36	Management of chronic liver disease-associated severe thrombocytopenia in Spain: a view from the experts. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020, 112, 778-783.	0.3	2

#	ARTICLE	IF	CITATIONS
37	A new pattern in hepatitis A virus infection in an urban population. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020, 112, 178-182.	0.3	2
38	Metabolic bone disease in patients diagnosed with inflammatory bowel disease from Spain. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481986215.	3.2	10
39	HIV Coinfection Predicts Failure of Ledipasvir/Sofosbuvir in Treatment-Naïve Noncirrhotic Patients With HCV Genotype 1. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz214.	0.9	4
40	Clinical Utility of a Risk-Adapted Protocol for the Evaluation of Coronary Artery Disease in Liver Transplant Recipients. <i>Liver Transplantation</i> , 2019, 25, 1177-1186.	2.4	16
41	β-blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. <i>Lancet</i> , The, 2019, 393, 1597-1608.	13.7	375
42	Addressing Profiles of Systemic Inflammation Across the Different Clinical Phenotypes of Acutely Decompensated Cirrhosis. <i>Frontiers in Immunology</i> , 2019, 10, 476.	4.8	134
43	It takes two eyes to see in depth. <i>Journal of Hepatology</i> , 2019, 70, 790-791.	3.7	1
44	Long-term albumin administration in patients with decompensated cirrhosis. It is time for a reappraisal. <i>Liver International</i> , 2019, 39, 45-48.	3.9	9
45	Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe. <i>Journal of Hepatology</i> , 2019, 70, 398-411.	3.7	225
46	Enfermedad hepática por alcohol. Guías de práctica clínica. Documento de consenso auspiciado por la AEEH. <i>Gastroenterología Y Hepatología</i> , 2019, 42, 657-676.	0.5	12
47	Familial low phospholipid-associated cholelithiasis resulting from an autosomal dominant ABCB4 mutation. <i>Revista Espanola De Enfermedades Digestivas</i> , 2019, 111, 806-808.	0.3	1
48	Meta-analysis of individual patient data of albumin dialysis in acute-on-chronic liver failure: focus on treatment intensity. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 1756284819879565.	3.2	6
49	Association Between Portosystemic Shunts and Increased Complications and Mortality in Patients With Cirrhosis. <i>Gastroenterology</i> , 2018, 154, 1694-1705.e4.	1.3	162
50	Enoxaparin does not ameliorate liver fibrosis or portal hypertension in rats with advanced cirrhosis. <i>Liver International</i> , 2018, 38, 102-112.	3.9	21
51	Cardiac function, A key component in evaluation for liver transplant. <i>Liver Transplantation</i> , 2018, 24, 7-8.	2.4	8
52	Comparison of Two Protocols of Carbon Tetrachloride-Induced Cirrhosis in Rats “Improving Yield and Reproducibility. <i>Scientific Reports</i> , 2018, 8, 9163.	3.3	49
53	Preconditioning by portal vein embolization modulates hepatic hemodynamics and improves liver function in pigs with extended hepatectomy. <i>Surgery</i> , 2017, 161, 1489-1501.	1.9	15
54	Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort. <i>Journal of Hepatology</i> , 2017, 66, 1138-1148.	3.7	159

#	ARTICLE	IF	CITATIONS
55	Left ventricular systolic function is associated with sympathetic nervous activity and markers of inflammation in cirrhosis. Hepatology, 2017, 65, 2019-2030.	7.3	43
56	Pressure volume curves in cirrhosis: More than meets the eye. Journal of Hepatology, 2017, 67, 656-657.	3.7	2
57	Efficacy and safety of daclatasvir-based antiviral therapy in hepatitis C virus recurrence after liver transplantation. Role of cirrhosis and genotype 3. A multicenter cohort study. Transplant International, 2017, 30, 1041-1050.	1.6	6
58	Acute on chronic liver failure: Are we ready to predict?. Liver International, 2017, 37, 1449-1450.	3.9	0
59	Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis. Gastroenterology, 2017, 153, 1273-1283.e1.	1.3	210
60	Enfermedades vasculares del h�gado. Gu�as Cl�nicas de la Sociedad Catalana de Digestolog�a y de la Asociaci�n Espa�ola para el Estudio del H�gado. Gastroenterolog�a Y Hepatolog�a, 2017, 40, 538-580.	0.5	20
61	De novo autoimmune hepatitis after liver transplantation: A focus on glutathione S-transferase theta 1. Liver Transplantation, 2017, 23, 75-85.	2.4	7
62	Endoscopically placed stents: a useful alternative for the management of refractory benign cervical esophageal stenosis. Revista Espanola De Enfermedades Digestivas, 2017, 109, 510-515.	0.3	8
63	Determinants of platelet count are different in patients with compensated and decompensated cirrhosis. Liver International, 2016, 36, 232-239.	3.9	10
64	Acute liver failure caused by mushroom poisoning: still a fork in the road. Liver International, 2016, 36, 952-953.	3.9	6
65	Liver Support With Albumin Dialysis Reduces Hepatitis C Virus Viremia and Facilitates Antiviral Treatment of Severe Hepatitis C Virus Recurrence After Liver Transplantation. Therapeutic Apheresis and Dialysis, 2016, 20, 189-196.	0.9	1
66	Impact of anticoagulation on upper gastrointestinal bleeding in cirrhosis. A retrospective multicenter study. Hepatology, 2015, 62, 575-583.	7.3	105
67	A gut solution for hepatic encephalopathy. Hepatology, 2015, 61, 2107-2009.	7.3	1
68	A new role for reticulon-4B/NOGO-B in the intestinal epithelial barrier function and inflammatory bowel disease. American Journal of Physiology - Renal Physiology, 2015, 308, G981-G993.	3.4	17
69	Molecular Adsorbent Recirculating System and Bioartificial Devices for Liver Failure. Clinics in Liver Disease, 2014, 18, 945-956.	2.1	24
70	Validation of Noninvasive Indices of Global Systolic Function in Patients With Normal and Abnormal Loading Conditions. Circulation: Cardiovascular Imaging, 2014, 7, 164-172.	2.6	55
71	A Histologic Scoring System for Prognosis of Patients With Alcoholic Hepatitis. Gastroenterology, 2014, 146, 1231-1239.e6.	1.3	353
72	Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: The RELIEF trial. Hepatology, 2013, 57, 1153-1162.	7.3	452

#	ARTICLE	IF	CITATIONS
73	Liver Support Systems: Will They Ever Reach Prime Time?. Current Gastroenterology Reports, 2013, 15, 312.	2.5	23
74	Early transplanted liver performance and indocyanine green clearance. Liver Transplantation, 2010, 16, n/a-n/a.	2.4	0
75	Risk factors for developing <i>de novo</i> autoimmune hepatitis associated with anti-glutathione S-transferase T1 antibodies after liver transplantation. Liver Transplantation, 2009, 15, 530-539.	2.4	52
76	Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy. Journal of Hepatology, 2008, 48, 229-236.	3.7	284
77	Antibodies Against Glutathione S-Transferase T1 (GSTT1) in Patients With GSTT1 Null Genotype as Prognostic Marker: Long-Term Follow-Up After Liver Transplantation. Transplantation, 2007, 83, 1126-1129.	1.0	38
78	Response to steroids in <i>de novo</i> autoimmune hepatitis after liver transplantation. Hepatology, 2002, 35, 349-356.	7.3	164
79	Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology, 2002, 36, 1367-1373.	7.3	121
80	Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: A meta-analysis. Hepatology, 2002, 35, 609-615.	7.3	401
81	Reply:. Hepatology, 2002, 36, 1024-1025.	7.3	0
82	Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology, 2002, 36, 1367-1373.	7.3	113
83	Multicenter Randomized Controlled Trial of Terlipressin Versus Sclerotherapy in the Treatment of Acute Variceal Bleeding: The TEST Study. Hepatology, 2000, 32, 471-476.	7.3	196
84	Carvedilol, a new nonselective beta-blocker with intrinsic anti-alpha ₁ -adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis. Hepatology, 1999, 30, 79-83.	7.3	158
85	Portal stenosis in liver transplantation. Treatment by endoluminal prosthesis. Transplant International, 1995, 8, 74-75.	1.6	4
86	Portal stenosis in liver transplantation. Treatment by endoluminal prosthesis. Transplant International, 1995, 8, 74-75.	1.6	3